FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   PERSEUS BIOTECH FUND PARTNERS LLC 2. Date of Event Requiring Statement (Month/Day/Year) 10/04/2007 3. Issuer Name and Ticker or Trading Symbol MAP Pharmaceuticals, Inc. [MAPP] (Last) (First) (Middle) 2099 PENNSYLVANIA AVE NW, SUITE 900 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) WASHINGTON, DC 20006-1813 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	  (4)	  (4)	Common Stock	610,168	$ (4)	D (1) (2) (3)	Â
Series B Convertible Preferred Stock	  (5)	  (5)	Common Stock	1,403,766	$ (5)	D (1) (2) (3)	Â
Series C Convertible Preferred Stock	  (6)	  (6)	Common Stock	828,147	$ (6)	D (1) (2) (3)	Â
Series D Convertible Preferred Stock	  (7)	  (7)	Common Stock	784,683	$ (7)	D (1) (2) (3)	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
PERSEUS BIOTECH FUND PARTNERS LLC 2099 PENNSYLVANIA AVE NW SUITE 900 WASHINGTON, DC 20006-1813	Â	  X	Â	Â
PERSEUSPUR LLC 2099 PENNSYLVANIA AVE NW STE 900 WASHINGTON, DC 20006-1813	Â	  X	Â	Â
PEARL FRANK H 2099 PENNSYLVANIA AVENUE NW SUITE 900 WASHINGTON, DC 20003	Â	  X	Â	Â

Signatures

/s/ Kenneth M. Socha, Senior Managing Director (8)		10/04/2007
**Signature of Reporting Person		Date
/s/ Kenneth M. Socha, Senior Managing Director (9)		10/04/2007
**Signature of Reporting Person		Date
/s/ Kenneth M. Socha, Attorney-in-Fact (10)		10/04/2007
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All of the securities reported herein (the "Shares") are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"). Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"), is the general partner of Perseus-Soros.
(2)	SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), is one of two managing members of Perseus-Soros Partners (see footnote 3). SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC"). Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC. Each of George Soros, Robert Soros and Jonathan Soros may be deemed to have voting power and/or dispositive power over the Shares held for the account of Perseus-Soros.
(3)	Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners") is one of two managing members of Perseus-Soros Partners. Perseuspur, L.L.C., a Delaware limited liability company ("Perseuspur"), is the managing member of Perseus Partners. Mr. Frank Pearl ("Mr. Pearl") individually owns 72.7% of Perseuspur. He also is the sole director and sole shareholder of Rappahannock Investment Company, a Delaware corporation, which in turn owns the remaining 27.3% of Perseuspur. Mr. Pearl in such capacity may be deemed a beneficial owner of the Shares held for the account of Perseus-Soros.
(4)	All of the outstanding shares of the Issuer's Series A Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(5)	All of the outstanding shares of the Issuer's Series B Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(6)	All of the outstanding shares of the Issuer's Series C Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(7)	All of the outstanding shares of the Issuer's Series D Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
  Remarks: (8)  Mr. Socha is signing in his capacity as Senior Managing Director of Perseuspur, LLC, as Managing Member of Perseus  BioTech Fund Partners, LLC. (9)  Mr. Socha is signing in his capacity as Senior Managing Director  of Perseuspur, LLC. (10)  Mr. Socha is signing in his capacity as Attorney-in-Fact for Mr. Pearl. This Form 3 is being filed in two parts due to the large number of reporting persons. This filing is filed by the  Reporting Persons listed in Footnote 3 above. An accompanying filing is filed, on the date hereof, by the Reporting Persons  listed in Footnotes 1 and 2 above. Both filings relate to the same series of transactions described above. Exhibits 24.1 - Power of Attorney for Mr. Pearl 99.1

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.